R&D Trends

23andMe launches national TV campaign

Friday, August 9, 2013 12:55 PM

23andMe, a personal genetics company, has launched Portraits of Health, the company’s first television advertising campaign. The campaign focuses on educating consumers about how understanding their DNA can help them make more informed and proactive health decisions.

More... »

Berg, Department of Defense partner for prostate cancer research

Friday, August 9, 2013 12:48 PM

Berg, a biopharmaceutical company researching health solutions through a data-driven, biological research approach, has partnered with the U.S. Department of Defense (DoD) under a cooperative R&D agreement with the Uniformed Services University of the Health Sciences' (USU) Center for Prostate Disease Research (CPDR) and The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) for prostate cancer research.

More... »

Ensemble Therapeutics, Novartis collaborate

Wednesday, August 7, 2013 11:51 AM

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, has initiated a two-part R&D collaboration with Novartis. The companies have entered into a strategic development agreement for Ensemble's most advanced proprietary program that targets the inflammatory cytokine IL-17, and for a new program to discover novel small molecule treatments against undisclosed drug targets specified by Novartis using Ensemble's proprietary drug discovery platforms.

More... »

Medicines Patent Pool, Roche sign HIV agreement

Tuesday, August 6, 2013 10:01 AM

The Medicines Patent Pool and Roche have signed an agreement to increase access in 138 developing countries to Roche’s valganciclovir, a key oral medicine to treat cytomegalovirus (CMV), a viral infection that can cause blindness in people with HIV, by making it up to 90% cheaper than current prices. The companies also will enter into licensing and technology transfer negotiations to encourage the development of internationally approved quality generic versions of valganciclovir.

More... »

PharmAthene, Theraclone Sciences merge

Monday, August 5, 2013 11:58 AM

PharmAthene and Theraclone Sciences, a privately-held monoclonal antibody (mAb) discovery and development company, have signed a definitive merger agreement.

More... »

Teijin Pharma, Amgen collaborate for autoimmune diseases

Monday, August 5, 2013 11:57 AM

Teijin Pharma has entered into a collaborative agreement with Amgen to discover, develop and commercialize small molecule drugs that target RORγ. The agreement grants Amgen an option to obtain a worldwide (excluding Japan) exclusive license to compounds discovered in the joint research collaboration, while Teijin Pharma will hold exclusive rights in Japan. Teijin Pharma will also have the right to co-promote potential products in select Asian markets.

More... »

Bionomics, Merck ink $172 million research collaboration

Thursday, August 1, 2013 11:31 AM

Bionomics has announced an agreement with Merck to discover and develop novel small molecule candidates for the treatment of chronic pain, including neuropathic pain. The initial period of the research program will be two years. 

More... »

La Jolla Institute, Kyowa Hakko Kirin extend research collaboration

Thursday, August 1, 2013 11:00 AM

La Jolla Institute for Allergy and Immunology and Kyowa Hakko Kirin California (KKC), a global specialty pharmaceutical company, have signed a new partnership agreement through the end of 2018.

More... »

AstraZeneca, FibroGen collaborate to develop and commercialize FG-4592

Wednesday, July 31, 2013 11:51 AM

AstraZeneca and biotechnology company FibroGen have entered into a collaboration to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), which also may be extended to other anemia indications.

More... »

Array BioPharma, Celgene announce collaboration

Wednesday, July 31, 2013 11:49 AM

Array BioPharma will collaborate with New Jersey-based biopharmaceutical company Celgene for an Array-invented preclinical development program targeting a novel inflammation pathway.  Array will receive an up-front payment of $11 million and Celgene will have an exclusive option to license multiple clinical development candidates. Array is entitled to receive potential milestone payments of up to $376 million based upon achieving certain development, regulatory and sales objectives. Array is also entitled to receive royalties on net sales of all drugs and will retain all rights to the program if Celgene does not exercise its option.

More... »